Allergan Completes Acquisition of Aczone Gel

Allergan Completes Acquisition of Aczone Gel

Allergan Completes Acquisition of Aczone Gel

Topical treatment for acne sells for $150 million

Allergan, Inc.’s wholly-owned subsidiary, Allergan Sales, LLC, and QLT USA, Inc., a wholly-owned subsidiary of QLT Inc. announced the completion of Allergan’s acquisition of QLT’s Aczone (dapsone) Gel 5% product, a topical treatment for acne.

 “We are pleased with the opportunity to grow our franchise in medical dermatology where there is a continuous need for new treatment options and strong growth potential,” said David E.I. Pyott, Allergan’s chairman of the board and chief executive officer. “Building upon our more than 10 years of success with Tazorac (tazarotene), we will now offer dermatologists the only acne treatment with dapsone in a topical formulation to provide to their patients in North America.”

Allergan paid approximately $150 million for all assets relating to Aczone Gel 5%. Allergan will not alter financial guidance for 2008 as a result of the transaction. Allergan expects to launch Aczone Gel 5% in the fourth quarter of 2008 in the United States and Canada.

Boutique executive search services with best in class global network, contacts and market mastery.

Deeply connected and engaged personal service approach, long-term investment in client community and 25 year history of strong relations with both Multi-National leaders and Private Equity partners.